logo
Will Nuclear Fusion Soon Be the ‘Norm?'

Will Nuclear Fusion Soon Be the ‘Norm?'

Epoch Times27-05-2025

Commentary
The dream of humanity to imitate the forces that created their habitat has been alive for at least as far back as the time when humans with a single language decided to build a city with a tower that reached the heavens. For such a people, 'nothing they plan will be impossible to them,' it is recorded.
For at least the same time frame, humanity has sought comfort through technology. While primitive heat producers like coal and wood are still used today, the discovery that petroleum, natural gas, and even moving water could generate a newly discovered phenomenon known as 'electricity' transformed the industrial revolution into the modern era.
Not until the 1930s did German scientists build on Enrico Fermi's discovery that neutrons could split atoms to recognize that splitting atoms would release significant energy—energy that could be used for both bombs and electricity generation. By the 1950s, scientists began building nuclear fission-based power plants that today provide about a tenth of the world's electricity.
Scientists and engineers also began to envision the potential of nuclear fusion—the reaction of light atomic nuclei powers the sun and the stars. Since that time, they have worked feverishly, but with little success, to replicate this energy-rich reaction using deuterium and tritium.
One group of scientists and engineers decided to try an alternative approach.
Related Stories
5/22/2025
5/21/2025
Founded in 1998, California-based TAE Technologies has been developing a reactor that runs on proton-boron aneutronic fusion—that is, a fusion reaction that fuses a hydrogen nucleus with non-radioactive boron-11 instead of fusing hydrogen isotopes of deuterium and tritium. Their goal is to develop commercial fusion power with the cleanest-possible environmental profile.
All efforts at fusion require chambers that can withstand temperatures of millions of degrees Celsius and immense pressure that are needed to fuse two isotopes together. To accomplish this requires huge amounts of energy—and until recently, more energy than the fusion produced.
Most fusion researchers, including those building the ITER project being built in France, rely on a donut-shaped tokamak reactor chamber, in which a stream of plasma must be held away from its walls by electromagnets for any energy to be produced. The tokamak design uses a toroidal magnetic field to contain the hydrogen plasma and keep it hot enough to ignite fusion.
Sadly, as with ITER, project costs have soared and timeframes have fallen by the wayside despite occasional breakthroughs. Over decades, tokamak designs became gigantic, with huge superconducting magnetic coils to generate containment fields; they also had huge, complex electromagnetic heating systems.
Spurred by the failures of wind and solar to fully satisfy the desire for 'clean energy,' governments and private investors began investing heavily into fission and fusion projects. Oak Ridge, Tennessee, has tapped into a $60 million state fund intended to bolster both fission and fusion energy in atomic energy's American birthplace.
New
The old method used for a stellarator reactor relied on perturbation theory. The new method, which relies on symmetry theory, is a game changer. It can also be used to identify holes in the tokamak magnetic field through which runaway electrons push through their surrounding walls and greatly reduce energy output.
The TAE Technology reactor is entirely different than any of the tokamak or stellarator fusion chambers. In 2017, the company introduced its fifth-generation reactor, named Norman, which was designed to keep plasma stable at 30 million C. Five years later the machine had proven capable of sustaining stable plasma at more than 75 million C.
That success enabled TAE to secure sufficient funding for its sixth-generation Copernicus reactor and to envision the birth of its commercial-ready Da Vinci reactor. But in between, TAE developed Norm.
Norm uses a different type of fusion reaction and a new reactor design that exclusively produces plasma using neutral beam injections. The TAE design dumps the toroidal field in favor of a linear magnetic field that is based on the 'field-reversed configuration' (FRC) principle, a simpler, more efficient way to build a commercial reactor.
Instead of massive magnetic coils, FRC makes the plasma produce its own magnetic containment field. The process involves accelerating high-energy hydrogen ions and giving them a neutral charge, then injecting them as a beam into the plasma. That causes the beams to be re-ionized as the collision energy heats the plasma to set up internal toroidal currents.
Norm's neutral beam injection system has cut the size, complexity, and cost, compared to that of Norman, by up to 50 percent. But not only is an FRC reactor smaller and less expensive to manufacture and operate, says TAE, it can also produce up to 100 times more fusion power output than a tokamak—based on the same magnetic field strength and plasma volume.
The FRC reactor also can run on proton-boron aneutronic fusion, which, instead of producing a neutron it produces three alpha particles plus a lot of energy. The fewer neutrons also do less damage to the reactor; the energy being released as charged particles is easier to harness. Less shielding is required, and, perhaps best of all, boron-11 is relatively abundant and not radioactive.
So, while 'Norm' may not be the final step in developing commercial fusion energy, TAE's hope is that fusion energy will the 'norm' as early as the mid-1930s. FRC technology has materially de-risked Copernicus, according to TAE CEO Michi Binderbauer.
If Norm is as advertised, it will accelerate the pathway to commercial hydrogen-boron fusion—a safe, clean, and virtually limitless energy source.
But is humanity ready for free energy to be the 'norm?'
From
Views expressed in this article are opinions of the author and do not necessarily reflect the views of The Epoch Times.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How to watch Apple's WWDC 2025 keynote
How to watch Apple's WWDC 2025 keynote

TechCrunch

timean hour ago

  • TechCrunch

How to watch Apple's WWDC 2025 keynote

Apple is hosting its developer-focused Worldwide Developer Conference for 2025 from June 9 to 13. The event's keynote is scheduled for June 9 at 1 p.m. ET/10 a.m. PT. The company is expected to unveil changes to its operating systems iOS, iPadOS, macOS, watchOS, tvOS, and visionOS. You can watch the keynote and subsequent sessions through Apple's event page or head to Apple's YouTube channel to watch them. Alternatively, you can bookmark this page and watch the keynote through the embed below. The company is reportedly set to overhaul the design of its operating systems with the aim to make the design cohesive across surfaces and devices. We might also see a change in the naming scheme for operating systems — Apple is reportedly choosing to rename its operating systems iOS 26, iPadOS 26, watchOS 26, and tvOS 26, instead of sticking to the old version numbering. For developers, the company is reportedly planning an AI-powered vibe coding tool in partnership with Anthropic for a new version of its programming tool suite Xcode. Catch all the WWDC coverage on TechCrunch.

ASCO25: PanGIA Biotech's AI-based urine test for prostate cancer hits trial success
ASCO25: PanGIA Biotech's AI-based urine test for prostate cancer hits trial success

Yahoo

timean hour ago

  • Yahoo

ASCO25: PanGIA Biotech's AI-based urine test for prostate cancer hits trial success

With early detection of prostate cancer recognised as a critical part in reducing the disease's mortality rate, PanGIA Biotech has shared results from a study validating its artificial intelligence (AI)-based liquid biopsy in vitro diagnostic (IVD) for detecting early prostate cancer from urine samples. The US company's detection methodology involves analysing urinary biosignatures using AI and machine learning models, which the company asserts may prove beneficial over invasive biopsies or blood-based tests that may miss early-stage cases while also eliminating the need for sequencing. PanGIA's prospective study involved 197 biopsy-confirmed prostate cancer patients and 84 healthy controls, with the test demonstrating strong performance in detecting intermediate- and low-grade cancers, and high recall (>0.89) across Gleason scores 6 through 10. The AI/ML classification model was also found to be effective as measured by F1 score. The study's findings were presented at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place in Chicago, Illinois between 30 May and 3 June. 'This study confirms what we've believed from the start: there's power in non-invasive, data-driven diagnostics,' PanGIA CEO Holly Magliochetti. 'Our platform helps clinicians detect prostate cancer when intervention is most effective – without costly or invasive procedures.' Past research indicates that with early detection, the five-year survival rate for prostate cancer is over 99%. According to GlobalData's Pipeline Products database, there are 142 prostate cancer IVDs at active stages of development globally. Growing at a CAGR of 3.5%, the overall global IVD market is forecast to reach a valuation of around $45.9m by 2024, up from $32.4m in 2024, as per GlobalData analysis. In other prostate cancer news from ASCO 2025, researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. A recent large report by Philips on the passage of AI adoption and innovation in healthcare reflected that while clinicians are chiefly on board with the AI and recognise its value in healthcare settings, 46% of respondents stated that slow adoption of AI was contributing towards missed opportunities for early diagnosis and intervention. "ASCO25: PanGIA Biotech's AI-based urine test for prostate cancer hits trial success" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY
MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY

Yahoo

time2 hours ago

  • Yahoo

MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY

SOMERVILLE, Mass., June 3, 2025 /PRNewswire/ -- Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular data for predictive biology, today announces new Series A financing. The round was led by Lewis & Clark Partners and OMX Ventures, joined by Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia, among others. The Company will use its Series A proceeds to grow its model as a service (MaaS) business and expand its machine learning and scientific operations. Jack Geremia, Matterworks CEO and Co-Founder, "I am delighted to partner with Lewis & Clark and welcome Carolyn Fritz to the Company's Board of Directors as we accelerate machine intelligence innovations that tackle the unsustainable cost of life science R&D." Carolyn Fritz, Operating Partner at Lewis & Clark Partners, "In collaboration with its customers, Matterworks has repeatedly demonstrated its AI platform provides a step change reduction in the cost and throughput of mass spec quantitation. We are excited to partner with this team in accelerating commercialization of their transformational technology." Craig Asher, Managing Director from OMX Ventures, "Matterworks is leveraging AI to unlock a new data layer for biology by making mass spectrometry accessible to all biologists. It's a shift as transformative as single-cell sequencing and we are thrilled to support this exceptional team." About MatterworksMatterworks' Large Spectral Models (LSMs) productize self-supervised machine intelligence for direct machine interpretation of molecular-omic data. PyxisTM, released in 2024, is the first generative AI for complete untargeted molecular annotation, unlocking new data modalities for understanding and predicting complex biological outcomes. About Lewis & Clark PartnersLewis & Clark Partners is a St. Louis-based group of experienced investment professionals passionate about investing in companies at the forefront of science, health, food, and agriculture innovation. We invest in growth-stage companies poised to scale nationally or globally. As founders, operators, investors, and scientists, our seasoned investment team brings deep sector expertise and insight to every investment. About OMX VenturesOMX Ventures is a venture capital firm focused on investing in a new era of bioengineering and its application for better tools, medicines, foods, industrial products, and more. We specialize in early­ stage investments at the intersection of biology, big data, and Al, with a focus on therapeutics, bio tools, diagnostics, and synthetic biology platforms. View original content to download multimedia: SOURCE Matterworks Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store